Q2:23 Financial Results and Business Update
August 9, 2023
Nasdaq: IONS
On Today's Earnings Call
Brett Monia, Ph.D. | Richard Geary, Ph.D. |
Chief Executive Officer | Executive Vice President, Development |
Eric Swayze, Ph.D. | Eugene Schneider, M.D. |
Executive Vice President, Research | Executive Vice President, |
Chief Clinical Development Officer |
Beth Hougen
Chief Financial Officer
Onaiza Cadoret
Executive Vice President,
Chief Global Product Strategy and
Operations Officer
2
Forward-Looking Statements
This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of QALSODYTM (tofersen), SPINRAZA® (nusinersen), TEGSEDI® (inotersen), WAYLIVRA® (volanesorsen), eplontersen, olezarsen, donidalorsen, ulefnersen, pelacarsen, bepirovirsen, IONIS-FB-LRx, Ionis' technologies, and Ionis' other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2022, and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.ionispharma.com.
In this presentation, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. QALSODYTM is a trademark of Biogen. SPINRAZA® is a registered trademark of Biogen.
3
Introduction
Brett Monia, Ph.D. Chief Executive Officer
Important Achievements in the First Half of 20231
• | QALSODY: approved by FDA for SOD1-ALS2 | |
Late-Stage | • | Eplontersen: |
- PN: December 2023 PDUFA date; on track for oUS submissions | ||
Pipeline | • | - CM: largest study in ATTR-CM now fully enrolled; data as early as H1:2025 |
Olezarsen: Ph3 FCS data expected H2:23 | ||
• | Donidalorsen: Ph3 study fully enrolled; data expected H1:24 |
Commercial Readiness
Financial Foundation
- On track to launch eplontersen, olezarsen and donidalorsen
- Co-commercializingeplontersen with AstraZeneca in the US
- Independently launching olezarsen and donidalorsen
- Key functions in place: global product strategy, market access, brand teams, etc.
- On track to achieve 2023 financial guidance
- $2.4 billion3 in cash enables investment to drive increasing value
- Successfully refinanced 2024 convertible notes to further strengthen balance sheet
Positioned
For
Substantial
Revenue
Growth
5 1. Timing expectations based on current assumptions and subject to change 2. For important prescribing and safety information, please refer to: www.qalsody.com3. Cash, cash equivalents and short-term investments at June 30, 2023.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ionis Pharmaceuticals Inc. published this content on 09 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2023 15:36:28 UTC.